Forest Laboratories Inc

More

• Forest Labs climbs as CEO announces retirement Thursday, 23 May 2013 | 3:58 PM ET

  NEW YORK-- Shares of Forest Laboratories Inc. rose to a year high Thursday after the drugmaker said Howard Solomon, its CEO for 36 years, will retire at the end of 2013..

• Forest Labs CEO Howard Solomon to retire Thursday, 23 May 2013 | 10:33 AM ET

  NEW YORK-- Forest Laboratories Inc. said Thursday that longtime executive Howard Solomon will retire as president and CEO at the end of 2013..

• Forest Labs' longtime CEO Solomon to step down at year-end Thursday, 23 May 2013 | 9:40 AM ET

  May 23- Forest Laboratories Inc said on Thursday that Howard Solomon, who has led the biotech firm since 1977, will retire as chief executive officer at the end of this year and the company will name a successor by that time. Forest Labs adopted a shareholder rights plan last year after investor Carl Icahn built up a more than 10 percent stake in the company.

• Almirall, Forest to seek approval for inhaler drug in US, Europe Thursday, 2 May 2013 | 3:47 AM ET

  MADRID, May 2- Spain's Almirall and Forest Laboratories said on Thursday that results of a second phase III clinical trial for a new inhaler were positive and they will seek regulatory approval to sell the drug by the end of the year.

• Almirall, Forest to seek approval for inhaler drug in US, Europe Thursday, 2 May 2013 | 3:47 AM ET

  MADRID, May 2- Spain's Almirall and Forest Laboratories said on Thursday that results of a second phase III clinical trial for a new inhaler were positive and they will seek regulatory approval to sell the drug by the end of the year.

• BRIEF-Forest Laboratories and Almirall report positive results for the second late-stage study Wednesday, 1 May 2013 | 2:22 PM ET

  May 1- Forest Laboratories Inc:. *Forest Laboratories and almirall announce positive results for the second. *Regulatory filings with the United States food& drug and European.

• Early Movers: DD, TRV, UTX & More Tuesday, 23 Apr 2013 | 8:13 AM ET

  

  Some of the names on the move ahead of the open.

• A Make-or-Break Week Ahead for the Stock Market Saturday, 20 Apr 2013 | 12:30 AM ET

  

  It's make-or-break time for the first-quarter earnings season, and it comes just as the stock market is showing signs of strain.

• Early Movers: KO, GS, JNJ & More Tuesday, 16 Apr 2013 | 8:11 AM ET

  

  Some of the names on the move ahead of the open.

• Almirall, Forest report positive results in inhaler trial Tuesday, 16 Apr 2013 | 2:58 AM ET

  MADRID, April 16- Spain's Almirall and Forest Laboratories said results of a first phase III clinical trial for Almirall's Genuair inhaler were positive and they would seek regulatory approval to sell the drug if further results proved positive.

• UPDATE 1-Optimer shares rise after report names Glaxo, Cubist as potential buyers Tuesday, 2 Apr 2013 | 2:29 PM ET

  *Optimer could get $15- $16/ shr- analyst. April 2- Shares of Optimer Pharmaceuticals Inc rose as much as 24 percent after a Bloomberg report said GlaxoSmithKline Plc and Cubist Pharmaceuticals Inc were among those interested in buying the antibiotic maker. The report also named AstraZeneca PLC and Japan's Astellas Pharma Inc as potential buyers.

• ANALYSIS-Antibiotics crisis prompts rethink on risks, rewards Monday, 18 Mar 2013 | 12:06 AM ET

  *Big Pharma retreat leaves antibiotic pipeline bare. *Low prices and limited usage key deterrents for industry. LONDON, March 18- Thirty years ago, when the world faced the terrifying prospect of an untreatable disease known as AIDS, big drugmakers scented an opportunity and raced to develop new medicines.

• US STOCKS-Wall St eyes lower open on debt limit, profit worries Tuesday, 15 Jan 2013 | 9:07 AM ET

  Wall Street was set to open lower on Tuesday as investors fretted over the debate brewing in Washington over raising the U.S. borrowing limit as well as what is expected to be a lackluster earnings season. The United States could default on its debt if Congress does not increase the borrowing limit.

• UPDATE 1-Forest posts loss as antidepressant sales plummet Tuesday, 15 Jan 2013 | 9:05 AM ET

  *Forest Labs posts much wider-than-expected loss.

• Early Movers: LEN, FRX, LULU & More Tuesday, 15 Jan 2013 | 7:51 AM ET

  

  Some of the names on the move ahead of the open.

• Forest posts 3rd-qtr loss as antidepressant sales plummet Tuesday, 15 Jan 2013 | 7:22 AM ET

  Jan 15- Forest Laboratories Inc on Tuesday posted a fiscal third-quarter loss as sales of its antidepressant Lexapro continued to be buffeted by generic competition. The company posted a net loss in the quarter that ended Dec. 31, of $153.6 million, or 58 cents a share, compared with a profit of $278.4 million, or $1.04 a year ago.

• Stocks Looking Beyond Debt Ceiling, for Now Monday, 14 Jan 2013 | 8:58 PM ET

  

  Stocks are so far looking past the brewing congressional debt ceiling drama but that could change quickly if it becomes very contentious.